RIDDLE&CODE
RIDDLE&CODE Energy Solutions, a subsidiary firm of the leading European blockchain interface company RIDDLE&CODE, together with the largest energy provider in Austria, Wien Energie, have announced the successful launch of a blockchain-powered energy tokenization platform called MyPower. The platform puts everyday consumers in charge of a co-created energy future by offering micro-investments and the tokenization of produced kilowatt-hours (kWh).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210607005004/en/
“Local energy communities and microgrids are expected to play an increasingly important role in addressing climate change challenges and the transition towards renewable and sustainable energy systems,” said Michael Strebl, CEO of Wien Energie. “However, the current market structure is inadequate to realise this vision, as consumers are practically excluded from participating in energy production and settlements. Blockchain has the potential to transform consumers into prosumers and active participants in the energy network.”
With the MyPower platform, which combines RIDDLE&CODE’s deep next-gen technology expertise with Wien Energie’s industry know-how, the two companies have managed to bridge this gap. As part of the project, RIDDLE&CODE Energy Solutions provides key management, tokenization and custody services and utilises Intel® Software Guard Extensions (Intel® SGX) to deliver the highest level of security.
The blockchain-powered platform enables consumers to participate in both energy consumption and production and benefit from using green energy. MyPower tokenizes solar photovoltaic (PV) assets and allows consumers to purchase shares in PV plants across Austria. At the MVP stage of the project, shares of a small, local PV plant were sold to a limited number of consumers. In return for their participation, consumers received a certain number of tokens, based on the amount of energy produced by the PV plant. The accumulated tokens could then be used for various purposes, such as paying electric bills.
“Confidential computing with Intel® Software Guard Extensions enables companies to leverage the benefits of confidential computing and allows data owners to remain in control of their sensitive data,” says Paul O’Neill, Senior Director, Business Development in Intel’s Confidential Computing Group. “RIDDLE&CODE's launch with Wien Energy demonstrates how Intel® SGX can help to deliver the security foundation needed to build and deploy a new era of dynamic and cost-effective networks. Intel® SGX offers hardware-based memory encryption that isolates specific application code and data in memory. Intel® SGX allows RIDDLE&CODE to allocate private regions of memory, called enclaves, which are designed to be protected from processes running at higher privilege levels.”
“Through the tokenization of both digital and physical assets, RIDDLE&CODE enables new business models in the financial, mobility and, of course, energy industries,” said Thomas Fürstner, Founder and CTO of RIDDLE&CODE. “Together with Wien Energie, we will unlock the full potential of the energy marketplaces and provide consumers with a platform that is both flexible and trustworthy.”
Please download related images to use in your articles from www.riddleandcode.com//press-mypower .
RIDDLE&CODE Energy Solutions
RIDDLE&CODE Energy Solutions, a subsidiary firm of the leading European blockchain interface company RIDDLE&CODE, provides the blockchain-powered infrastructure that enables resilient, low-cost and green electricity production and builds a foundation for a decentralised urban energy marketplace.
More information: www.riddleandcode.com
Wien Energie
Wien Energie is one of Austria’s largest utility providers, responsible for ensuring the reliable and eco-friendly supply of electricity, natural gas and heating to around two million people, 230,000 businesses and industrial facilities, and 4,500 farms in the Greater Vienna metropolitan area. Wien Energie is also involved in a number of projects at European level.
More information: www.wienenergie.at .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210607005004/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom